Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term galantamine treatment in mild to moderately severe Alzheimer's disease
2007-002780-27Phase 3Terminated
- Sponsor
- Johnson & Johnson
- Start
- Sep 2007
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Galantamine with Placebo (2 arms). Primary endpoint: Primary cognitive endpoint. Started Sep 2007; status: terminated.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2007-002780-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002780-27.